Arcutis Biotherapeutics Reports 122% Revenue Growth to $99.2 Million in Q3 2025

Arcutis Biotherapeutics, Inc. reported significant financial performance improvements in its latest quarterly filing, with total revenues reaching $99.2 million for the three months ended September 30, 2025, compared to $44.8 million for the same period in 2024. This represents a 122% increase, driven primarily by strong sales of its flagship product, ZORYVE, which includes both cream and foam formulations. The company’s product revenue for the nine months ended September 30, 2025, was $246.6 million, a substantial increase from $125.2 million in the prior year. Notably, ZORYVE foam sales surged by 146% year-over-year, reflecting heightened demand for treatments of seborrheic dermatitis and plaque psoriasis.

Despite the revenue growth, Arcutis continues to face challenges with profitability. The company reported a net income of $7.4 million for the third quarter of 2025, a stark contrast to a net loss of $41.5 million in the same quarter of 2024. However, for the nine-month period, the company still recorded a net loss of $33.5 million, although this was an improvement from a loss of $129.3 million in the previous year. The increase in operating expenses, which totaled $90.7 million for the quarter, was attributed to higher costs associated with sales and marketing efforts as well as ongoing research and development activities.

Operationally, Arcutis has made strides in expanding its product offerings and market presence. The company launched ZORYVE cream 0.15% for atopic dermatitis in July 2024 and has received FDA approval for additional formulations, including ZORYVE cream 0.05% for young children, which is set to launch in October 2025. The company also entered into a co-promotion agreement with Kowa Pharmaceuticals to enhance its marketing efforts in the U.S. market. As of September 30, 2025, Arcutis had approximately 120.3 million shares outstanding, reflecting a slight increase from 117.8 million shares at the end of 2024.

In terms of liquidity, Arcutis reported cash, cash equivalents, restricted cash, and marketable securities totaling $191.4 million as of September 30, 2025, down from $228.6 million at the end of 2024. The company has an outstanding long-term debt of $100 million, which it plans to manage through its operational cash flows. The company believes its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months. However, it acknowledged the potential need for additional financing if cash flows from operations do not meet expectations.

Looking ahead, Arcutis remains focused on advancing its product pipeline and expanding its market share in dermatological treatments. The company anticipates continued investment in commercialization efforts for ZORYVE and ongoing clinical development for its other product candidates, including ARQ-234. While the recent financial results indicate a positive trajectory, the company cautioned that future profitability remains uncertain and will depend on various factors, including market conditions and the success of its product launches.